Telisotuzumab
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers[1].
Product Specifications
CAS Number
1781223-80-0
Product Name Alternative
ABT-700
UNSPSC
12352203
Target
Apoptosis; c-Met/HGFR
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/telisotuzumab.html
Purity
99.54
Solubility
10 mM in DMSO
Smiles
[Telisotuzumab]
Molecular Weight
(146.1 kDa)
References & Citations
[1]Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K6106404 1.0 µg DNA
Marveld3 sgRNA CRISPR Lentivector (Rat) (Target 3)
Sign In for Pricing
View Details C751K.9900.10 10 Assays
REMBRANDT® LSI 21q22-ISH digoxigenin detection assay
Sign In for Pricing
View Details 